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 Introduction 
 Neonatal diabetes mellitus (NDM) is a rare entity with 
an incidence of 1 in 400,000 neonates  [1, 2] . More than 
50% of cases are classifi ed as transient NDM (TNDM)  [3, 
4] . Typically, uniparental paternal isodisomy of chromo-
some 6 (UDP6), paternal duplications or methylation de-
fects at Chr 6q24 are found in TNDM  [5] . Insulin thera-
py has to be initiated and remission occurs within a few 
months to up to 2 years. Recently, the use of continuous 
subcutaneous insulin infusion (CSII) has been reported 
to be safe, more physiological and more accurate than 
injections  [1] . The management of NDM with insulin, 
however, is diffi cult with a signifi cant risk of hypoglyce-
mic episodes  [1] . Long-term microdialysis subcutaneous 
glucose monitoring (MSGM) is feasible in humans  [6] 
and its use in newborns has been reported  [7] . Such sys-
tems continuously perfuse dialysis fl uid through a semi-
permeable subcutaneous catheter and recollect the dialy-
sate for point-of-care analysis. A good correlation be-
tween subcutaneous and blood glucose levels was ob-
served in newborns and the procedure was suggested to 
reduce painful blood sampling and blood loss  [8] . 
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 Abstract 
 In neonatal diabetes mellitus (NDM), a rare genetic dis-
order, insulin therapy is required but the management 
is diffi cult. Frequent blood glucose determinations are 
necessary in most cases. Microdialysis subcutaneous 
glucose monitoring (MSGM) is feasible in neonates and 
has been proposed to reduce painful blood sampling and 
blood loss. We have applied long-term MSGM to a small-
for-date female newborn with transient NDM. We found 
a good correlation of subcutaneous and blood glucose 
concentration over a wide range of values. MSGM en-
abled a reduction in blood glucose determinations dur-
ing optimization of intravenous insulin treatment and 
initiation of continuous subcutaneous insulin infusion. 
We conclude that long-term MSGM is feasible and may 
reduce painful blood sampling and blood loss in NDM. 
Furthermore, long-term MSGM may hold a potential for 
avoiding hypoglycemic episodes and earlier discharge. 
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 We report here on a small-for-gestational-age (SGA) 
newborn with TNDM due to paternal UPD6. During ini-
tial intravenous insulin treatment and the transition to 
CSII, we used long-term MSGM. This is the fi rst report 
of MSGM in the management of neonatal diabetes. 
 Research Design and Methods 
 After an uneventful pregnancy, the female fetus was delivered 
at term by caesarean section. Birth weight was 2.75 kg (1.8th per-
centile, –2.1 SD), body length was 47 cm (1.9th percentile,
–2.1 SD). Blood glucose was 2.8 mmol/l 90 min after birth and
6.9 mmol/l at 19 h. Generalized edema and inappropriate sucking 
were observed. On day 4, body weight was 2.31 kg and prepran-
dial blood glucose was continuously rising to 13.3 mmol/l. On day 
5, when blood glucose was 23.8 mmol/l, administration of intrave-
nous insulin was initiated at a basal rate of 0.03 IU/kg    h. Intrave-
nous boluses were administered according to capillary blood glu-
cose concentrations and demand feeding. Management was diffi -
cult and episodes of hypoglycemia (blood glucose  ! 2.6 mmol/l) 
occurred. On day 13 the patient was transferred to our neonatal 
intensive care unit. Blood glucose management remained unsatis-
factory. Informed consent was obtained from the parents to initiate 
subcutaneous microdialysis and to perform genetic analyses. 
Screening for paternal UDP6 was performed by typing of micro-
satellite markers (D6S276, D6S1010, D6S308, D6S311, D6S430, 
D6S265). 
 Starting from postnatal day 20, MSGM was performed using a 
CMA 70 microdialysis catheter and a CMA 106 pump. Bedside 
analyses were performed on a CMA 600 Microdialysis Analyzer 
(CMA/Microdialysis AB, Solna, Sweden). The microdialysis pro-
cedure and point-of-care glucose analyses of the dialysate were per-
formed as described previously  [8] . Briefl y, the microdialysis cath-
eter was introduced into subcutaneous adipose tissue of the lateral 
thigh after transdermal local anesthesia with a 24-gauge intrave-
nous catheter. The steel and plastic cannulas were withdrawn such 
that only the semipermeable tip of the microdialysis catheter (0.6 
 ! 10 mm) remained in the subcutaneous tissue. A maximum re-
siding time of an individual catheter was defi ned as 1 week. The 
catheter was fi xed to the patient’s skin with a transparent adhesive 
foil and the portable pump (fl ow rate: 0.3   l/min) and a collecting 
microvial were connected. The nursing staff was instructed to re-
place the collecting microvial every 15 min and to perform bedside 
analysis of the dialysate. Blood glucose measurements in a clinical 
chemistry laboratory by an enzymatic method on an automated 
analyzer (ESAT 6660, Eppendorf, Hamburg, Germany) or bedside 
with a HemoCue B glucose analyzer (HemoCue, Grossostheim, 
Germany) were performed when believed necessary for clinical 
management. Microdialysis data were accessible to the clinician 
immediately. Abnormal MSGM values prompted blood glucose 
measurements. 
 CSII with a H-Tron ® plus pump (Disetronic, Burgdorf, Switzer-
land) was initiated on day 28 with a basal rate of 0.02 IU insulin/
kg    h and boluses for meals and correction of hyperglycemia. 
MSGM was continued until day 31. 
 Results 
 Typing of microsatellite markers revealed paternal 
UPD6 in our patient. The identity of the samples was 
confi rmed by microsatellite markers on other chromo-
somes. C-peptide (measured at day 28 of life) was below 
detection limit ( ! 0.5 ng/ml). 
 During the initial week of intravenous insulin treat-
ment with conventional capillary blood glucose monitor-
ing, the number of hypoglycemic episodes was high and 
remained high during the second week despite changing 
to fi xed 3-hourly feeds and more intensive blood glucose 
monitoring ( table 1 ). When MSGM was introduced dur-
ing intravenous insulin treatment in the 3rd week of treat-
ment the number of blood glucose determinations de-
creased while less hypoglycemic episodes were recorded 
( table 1 ). MSGM was continued during the transition to 
CSII. During this 4-day phase and the following 2 weeks, 
no hypoglycemia was observed. After fi nding a suitable 
Table 1. Capillary blood glucose determinations and hypoglycemic episodes during different phases of insulin treatment in a patient with 
neonatal diabetes
Mode of treatment and diagnostics Day
of life
Total 
hours
Blood glucose
determina-
tions
Blood glucose 
determinations
per 24 h (range)
Hypoglycemic
episodes
(per 24 h)
Initial intravenous insulin (demand feeding) 5–13 195 121 14.9 (10–24) 6 (0.74)
Intravenous insulin; fi xed feeds every 3 h 13–20 173 134 18.6 (16–23) 6 (0.83)
Intravenous insulin and MSGM 20–28 187 74 9.5 (8–11) 2 (0.26)
CSII and MSGM 28–31 68 27 9.5 (8–10) 0 
CSII without MSGM 31–44* 296 87 7.05 (6–11) 0
* Day of discharge.
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treatment mode, MSGM was discontinued on day 31 of 
life. For a total of 12 days of MSGM, 3 microdialysis 
catheters had to be introduced. One catheter was found 
displaced because of the infant’s activity. Another cath-
eter was removed immediately after positioning because 
of inadvertent puncture of a small vein since blood clots 
surrounding the catheter are expected to inhibit free 
equilibration of extracellular and microdialysis fl uids. No 
local complications were observed. The mean number of 
blood glucose measurements remained low during the fol-
lowing 2-week period ( table 1 ). After thoroughly instruct-
ing the parents, the patient was discharged on day 44. 
 Outpatient follow-up demonstrated decreasing insulin 
demand. At age 3½ months, remission occurred and in-
sulin treatment was discontinued. Adequate weight gain 
was observed during and after insulin therapy. At age 6 
months, body weight was 7.4 kg (72nd percentile), body 
length was 64 cm (16th percentile). HbA1C was 4.8%. 
Overall development was normal. 
 Conclusions 
 Neonatal diabetes represents a challenge for thera-
peutic management. Hypoglycemic episodes are likely 
to occur  [1] and many painful blood sampling proce-
dures appear necessary. In a case with transient neona-
tal diabetes, we demonstrated that long-term MSGM is 
feasible. Reduced subcutaneous tissue mass in a SGA 
newborn was not relevant for microdialysis function. A 
good correlation of subcutaneous and blood glucose 
concentration over a wide range of values ( fi g. 1 ) en-
abled early detection of rising and falling blood glucose 
and allowed therapeutic interventions. MSGM enabled 
a reduction in blood glucose determinations during op-
timization of intravenous insulin treatment and initia-
tion of CSII. 
 Studies are needed to address whether long-term 
MSGM reduces painful blood sampling and blood loss as 
compared to conventional management. Moreover, the 
use of MSGM may hold a potential for better blood glu-
cose control and earlier discharge of a newborn with dia-
betes mellitus. 
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 Fig. 1. Example of correlation of blood glu-
cose and microdialysis glucose concentra-
tions. During a 64-hour interval while in-
travenous insulin was administered, blood 
glucose values were reliably refl ected by mi-
crodialysis measurements over a wide range 
of concentrations (correlation coeffi cient 
r = 0.91). Note that due to the high frequen-
cy of microdialysis measurements, rising 
glucose levels with meals every 3 h are eas-
ily recognizable. 
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